TABLE 6.
Summary of adverse drug events.
| Type of interventions | Number of RCTs | Groups | Total sample size | Incidence | Detailed ADR events (number of cases) |
|---|---|---|---|---|---|
| PGE1+SMI vs. PGE1 | 0 | PGE1+SMI | 0 | — | — |
| PGE1 | 0 | — | — | ||
| PGE1+DCI vs. PGE1 | 1 | PGE1+DCI | 65 | 3.08% | Anorexia (1), constipation(1) |
| PGE1 | 65 | 4.62% | Diarrhea (1), Dizziness(1), Fever(1) | ||
| PGE1+DHI vs. PGE1 | 4 | PGE1+DHI | 147 | 0.00% | None |
| PGE1 | 144 | 0.00% | None | ||
| PGE1+HQI vs. PGE1 | 5 | PGE1+HQI | 433 | 16.86% | Dizziness (19), headache (17), pain at the injection site (36), allergies (1) |
| PGE1 | 415 | 14.70% | Dizziness (24), pain at the injection site (27), redness at the injection site (4), vomiting (5), diarrhea (1), | ||
| PGE1+SKI vs. PGE1 | 4 | PGE1+SKI | 136 | 0.74% | Pain and flushing at the injection site (1) |
| PGE1 | 116 | 0.00% | None | ||
| PGE1+SXTI vs. PGE1 | 2 | PGE1+SXTI | 96 | 0.00% | None |
| PGE1 | 90 | 0.00% | None | ||
| PGE1+XBJI vs. PGE1 | 1 | PGE1+XBJI | 30 | 0.00% | None |
| PGE1 | 30 | 0.00% | None |
SMI, Salvia miltiorrhiza injection; DCI, Danshen-Chuanxiongqin injection; DHI, Danhong injection; HQI, Huangqi injection; SKI, Shenkang injection; SXTI, Shuxuetong injection; XBJI, Xuebijing injection; PGE1, alprostadil injection.